Stay updated on KarXT Long-Term Safety in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the KarXT Long-Term Safety in Schizophrenia Clinical Trial page.

Latest updates to the KarXT Long-Term Safety in Schizophrenia Clinical Trial page
- Check5 days agoChange DetectedAdded Revision: v3.5.2; removed Schizophrenia, related topics: MedlinePlus Genetics, and Revision: v3.5.0.SummaryDifference0.2%

- Check12 days agoChange DetectedRelated topics Schizophrenia and MedlinePlus Genetics were added to the study page to provide broader context and improve discoverability.SummaryDifference0.1%

- Check19 days agoChange DetectedRemoved the Schizophrenia topic tag and related topics including MedlinePlus Genetics from the page; this affects navigation tags but does not alter the core trial content.SummaryDifference0.1%

- Check27 days agoChange DetectedSponsor information was updated to include Karuna Therapeutics, Inc., a Bristol Myers Squibb company, and schizophrenia- and MedlinePlus Genetics-related topics were added. The standalone term Karuna Therapeutics was removed.SummaryDifference0.3%

- Check34 days agoChange DetectedRevision metadata updated: added v3.5.0. Removed v3.4.3.SummaryDifference0.0%

- Check41 days agoChange DetectedRemoved the related topics 'Schizophrenia' and 'MedlinePlus Genetics' from the page. This reduces contextual tagging and external links but does not alter the study's core information or eligibility details.SummaryDifference0.1%

Stay in the know with updates to KarXT Long-Term Safety in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Long-Term Safety in Schizophrenia Clinical Trial page.